Search

Displaying results 5931 - 5940 of 10000 in total
  1. Drug

    PRX-ASL

    go.drugbank.com/drugs/DB17679
    Experimental

    PRX-ASL is an intracellular enzyme replacement therapy designed to replace the missing or defective enzyme in patients with argininosuccinate lyase deficiency.

  2. Drug

    MBL-HCV1

    go.drugbank.com/drugs/DB17776
    Investigational

    MBL-HCV1 is a monoclonal antibody developed to prevent the recurrence of hepatitis C virus (HCV) in patients receiving a liver transplant.

  3. Drug

    Sevuparin

    go.drugbank.com/drugs/DB15007
    Investigational

    Sevuparin is under investigation in clinical trial NCT03853421 (Placebo-controlled Study to Determine the Safety and Tolerability of Subcutaneous Doses of Sevuparin).

  4. Drug

    Salix alba bark

    go.drugbank.com/drugs/DB14274
    Approved

    Salix alba bark is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  5. Drug

    Benidipine

    go.drugbank.com/drugs/DB09231
    Investigational

    Benidipine has the formula 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester hydrochloride.

  6. Drug

    Jojoba oil

    go.drugbank.com/drugs/DB14252
    Approved

    Jojoba oil is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  7. Drug

    Scutellaria lateriflora

    go.drugbank.com/drugs/DB14339
    Approved

    Scutellaria lateriflora is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.

  8. Drug

    Cobitolimod

    go.drugbank.com/drugs/DB14819
    Investigational

    Cobitolimod is under investigation in clinical trial NCT03178669 (The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis).

  9. Drug

    KAHR-102

    go.drugbank.com/drugs/DB17427
    Investigational

    KAHR-102 is a dual signaling protein fusing cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) to the Fas-ligand (FasL).

  10. Drug

    HMI-103

    go.drugbank.com/drugs/DB17684
    Investigational

    HMI-102 is an investigational gene therapy designed to encode the phenylalanine-4-hydroxylase (PAH) gene, mutated in people with phenylketonuria.